€30m · Series A · Healthtech · Paris, France
Biolevate, a Paris-based platform automating scientific and regulatory work for life sciences organisations, has raised €30m in Series A funding. RAISE France and Orange Ventures co-led the round, with participation from MSD Global Health Innovation Fund, Station F and existing investor EQT Ventures. The company will use the capital to expand internationally, deepen its product and scale deployments, including through a new Boston office.
Biolevate says more than a dozen enterprise customers are using its software in production, annual recurring revenue grew twentyfold over the past year and its team has reached 50 people. Those are company-reported figures. Its platform structures scientific and regulatory knowledge so AI agents can support literature reviews, regulatory intelligence and other evidence-heavy workflows with traceability and human oversight.
Regulated AI wins by making evidence reusable
Life sciences teams cannot treat a generated answer as the final product: they need to trace conclusions back to validated studies, documents and rules. Biolevate is building around that constraint, turning scientific knowledge into reusable workflows rather than adding a generic assistant beside existing compliance systems.
The commercial advantage should compound if the same governed evidence can support several processes, from research synthesis to market access. But expansion raises the product burden too: every jurisdiction, therapeutic area and customer system adds new context that must remain auditable. The Series A finances that coverage while Biolevate tests whether evidence-grade automation can become infrastructure rather than a collection of pilots.
Explore this theme
Inside Complir’s $11M raise: Why product compliance is a strong use case for AI — Gustav Bang and Complir, hosted on EUVC · 16 September 2026. Complir’s account explains why regulated workflows favour domain-specific AI grounded in product records, a parallel to Biolevate’s evidence-first approach in life sciences.
